Kornimate/medical-research-clean huggingface dataset:
anxiety sensitivity treatment for heroin users

Conditions: Anxiety

Summary: anxiety sensitivity treatment for heroin users is a development project targeting mild and above levels of anxiety sensitivity that will involve the testing of a specialized protocol for improving treatment retention and outcomes for heroin dependent individuals in a residential substance use treatment. asth-hr will integrate established treatment modules such as healthy relationships, along with interoceptive exposure, affect management, and psycho-education exercises developed for anxiety prevention and treatment programs with standard substance use treatment.


Eligibility criteria:
inclusion criteria: * exhibit a score of 21 on a self-report measure of anxiety sensitivity * be in 28 days of residential substance use treatment. * meet criteria for current opioid dependence as determined by scid interview administered at intake. exclusion criteria: * evidence of limited mental competency * the inability to give informed, voluntary, written consent to participate * current psychosis * current bipolar disorder.

Keywords: anxiety sensitivity heroin
interleukin-17 (il-17) inhibitor in combination with tumor necrosis factor α (tnfα )inhibitor for the treatment of ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.


Eligibility criteria:
inclusion criteria: 1. male or female at least 18 years old; 2. diagnosed with as according to the 1984 new york modified criteria; 3. poor response after at least 2 nsaids (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to nsaids therapy; 4. basdai score of ≥ 4 and total back pain vas score of ≥ 4 at baseline; 5. subjects who need to take nsaids (including cox-1 or cox-2 inhibitors) as established treatment for as, and the nsaids should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study; 6. voluntary treatment with adalimumab and secukinumab; 7. appropriate contraceptive measures for women of childbearing age; 8. without other rheumatic diseases. 9. able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits) exclusion criteria: 1. with unstable vital signs, coma, mental and cognitive impairment; 2. patients with severe systemic diseases and other serious chronic diseases; 3. pregnant or lactating patients; 4. history of malignant tumor in the past 5 years; 5. positive test for the following infection markers: human immunodeficiency virus (hiv), hepatitis b, hepatitis c, syphilis antibody; 6. patients with active or recurrent history of infection; with active tuberculosis or have a history of active tuberculosis in the past; 7. moderate to severe heart failure (new york heart association grade 3-4); 8. allergic to any of the components of adalimumab (hs016) or secukinumab; 9. subjects who are participating in clinical research of other drugs; 10. in addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.

Keywords: ankylosing spondylitis secukinumab adalimumab
clinical trials of adjuvant androgen deprivation in localized prostate cancer

Conditions: Prostate Adenocarcinoma

Summary: the present study is a phase iii randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 gy) conformal radiotherapy in moderate high-risk prostate cancer patients. stratification will be performed by prognostic factors and by participating institution.


Eligibility criteria:
inclusion criteria: * histological proven adenocarcinoma of the prostate * stage: ct1c-3b n0m0 according to american joint committee on cancer (ajcc) tumor node metastasis (tnm) * prostatic specific antigen (psa)\<100 ng/ml * intermediate (t1-t2 with gleason score \[gs\] 7 and/or psa 10-20) * high risk (t3 and/or gs 8-10 and/or psa \> 20) * karnofsky index (ki) performance status ≥70% * written informed consent exclusion criteria: * t4 n1 m1, * previous surgical treatment (prostatectomy or cryosurgery) * neoadjuvant hormonal treatment \> 3 months. * history of pelvic radiotherapy (rt) * contraindications for radiotherapy * concomitant use of chemotherapy * serious psychiatric or medical condition * current synchronic malignancies

Keywords: patients with prostate adenocarcinoma
ain457 regimen finding extension study in participants with moderate to severe psoriasis

Conditions: Plaque-type Psoriasis

Summary: the purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

in the proof-of-concept study (cain457a2102/ nct00669916), ain457 was proven to be efficacious in the treatment of moderate to severe chronic plaque-type psoriasis. as a result, a phase iib regimen finding study had been started (cain457a2211/nct00941031). the data gathered in this extension study of the core study (cain457a2211)was used to expand the safety database of the compound for the treatment of moderate to severe chronic plaque-type psoriasis. the participants in the extension study continued to stay on the exact same treatment regimen they were taking when completing the core study. the extension trial was first designed to provide long-term safety data of up to 100 weeks of treatment (32 weeks in the core study plus 68 weeks in the extension study (part 1)), and an additional 12 weeks of treatment-free follow-up for participants who did not continue in the extension study. amendment 2 provided an additional 156 weeks of treatment (32 weeks in the core study plus 224 weeks in the extension study, equaling 256 weeks of total treatment (part 2)), before participants entered the 12 weeks of treatment-free follow-up. protocol amendment 3 extended the prolongation part of the study by up to 104 additional weeks of treatment (part 3) or until the drug was commercially available in the market of the country of participation, whichever occurred first.

Eligibility criteria:
key inclusion criteria: * patients who completed the core study cain457a2211. a patient is defined as having completed the core study if he/she completed the study up to and including visit 13 (f4) of the core study * patients must be able to understand and communicate with the investigator and comply with the requirement of the study and must given written, signed and dated informed consent before any study assessment is performed. * patients must be expected to benefit from the ongoing treatment with ain457, as assessed by the patient and investigator * male patients must consent to practice reliable contraception during the study and for 16 weeks after the last dose of study drug administration note: due to new data available from the toxicology studies, the need for male contraception was removed. key exclusion criteria: * patients who experience a second consecutive full relapse at visit 13 ( week f4) of the core study cain457a2211 * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until termination of gestation, confirmed by a positive hcg laboratory test (\> 5mlu/ml) * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment.

Keywords: chronic plaque-type psoriasis ain457 dermatology moderate to severe chronic plaque-type psoriasis
long-term quality of life of patients with a congenital heart disease, treated by surgery in adulthood at the brugmann hospital.

Conditions: Congenital Heart Disease

Summary: adults with a congenital heart disease, having undergone a surgical intervention or a re-do surgery in adulthood, are a growing group of subjects in the general population. this increase is explained by improved medical and surgical techniques, with a better survival rate as outcome. there is nowadays a growing interest in the quality of life of this group of subjects. however, studies give contradictory results. this can be explained on one hand by the vast majority of pathologies within this population, and on the other hand by the absence of a cardio-specific tool for quality of life measurement. the macnew questionnaire is cardio-specific. it allows an evaluation of the quality of life based on the exploration of three domains: physical, emotional and social. the aim of this study is: * to evaluate the quality of life of these patients, by using the macnew questionnaire * to explore the needs in terms of prevention, treatment and multi-disciplinary follow-up * to assess the mortality within this group of patients.


Eligibility criteria:
inclusion criteria: patients having had surgery in adulthood for a congenital heart disease, at the brugmann university hospital. the group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015 exclusion criteria: none

Keywords: macnew questionnaire quality of life
gpi+nbm dbs in parkinson's disease with mild cognitive impairment

Conditions: Parkinson Disease; Memory Disorders

Summary: this study examines the safety and feasibility of dbs in treating the movement and cognitive dysfunction in parkinson's disease (pd). globus pallidus interna (gpi) stimulation is an established treatment for the motor symptoms in pd, but it does not treat the cognitive symptoms that can also be seen in this condition. it is theorized that we can improve cognitive dysfunction by stimulating a part of the brain called the nucleus basalis of meynert (nbm), which releases a chemical (acetylcholine) and plays a role in memory and attention. by using a novel dbs system (vercise device) with 2 electrodes that are designed to stimulate the gpi and nbm, we can potentially target the motor and cognitive symptoms of pd with a single intervention.

neuronal loss within the cholinergic nucleus basalis of meynert (nbm) correlates with cognitive decline in dementing disorders such as alzheimer's disease and parkinson's disease (pd). deep brain stimulation targeting the globus pallidus interna (gpi) is an established treatment for the motor symptoms in parkinson's disease, and stimulating the nbm is believed to stimulate cognitive function. targeting these two regions was previously impossible because they require different frequency stimulations, but recent developments in dbs technology allow for the dual stimulation of these nuclei at different frequencies. this phase-ii double-blind cross-over pilot trial will investigate the motor and cognitive effects as well as the presence of adverse effects of combined nbm and gpi dbs. the main goal of this pilot trial is to demonstrate the feasibility and safety of the multi-targeting approach in 6 patients with pdd and disabling motor symptoms.

Eligibility criteria:
inclusion criteria: 1. pd-mci that affects multiple cognitive domains (including memory, visuo-spatial deficits etc.). diagnosis based on a comprehensive neuropsychological assessment (gold-standard) allowing the application of level ii mds diagnostic criteria (dubois et al. 2007) 2. pd fulfilling standard criteria for bilateral gpi dbs surgery 3. patient's ability to provide informed consent and comply with study protocol. exclusion criteria: 1. severe parkinson's disease dementia, preventing completion of the neuropsychological assessment, compliance with the study protocol, or ability to provide informed consent. 2. inability to be fluent in english. 3. unstable dose of any cognitive enhancing medication. 4. presence of other neurological disorders, severe active psychiatric conditions or previous brain surgery. other conditions contraindicating dbs, pet scanning or mri scanning.
the effect of related blood markers on diabetic peripheral neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: the goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy(dpn).

this is a multicenter study(approximately four) with over 1000 subjects.clinical data were collected by consulting the patient's electronic history. the data included demographic information, blood biochemical markers and electromyography. all participants provided their written informed consent to participate in this study.the study protocol was approved by the ethics committee of the first affiliated hospital of wenzhou medical university(ky-2022-r009).

Eligibility criteria:
inclusion criteria: * patients who had undergone nerve conduction examination by electromyography. exclusion criteria: * pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections; * patients with alcohol abuse; history of autoimmune liver disease, liver disease or abnormal liver function at baseline; * parathyroid diseases (including hyperthyroidism and hypothyroidism); * pancreatitis, pancreatectomy or any transplant; * patients with malignancy and any serious concomitant disease limit the existence of life expectancy

Keywords: diabetic peripheral neuropathy electromyography blood parameters
frequency analysis of carotid artery disease

Conditions: Carotid Artery Disease

Summary: the purpose of this study is to determine if carotid artery stenosis can be detected using an electronic stethoscope. this study will use a commercially available electronic stethoscope to record carotid sounds in patients with suspected carotid artery stenosis. the presence of absence of abnormal vessels will be confirmed by diagnostic ultrasound as part of normal patient care at this institution.


Eligibility criteria:
inclusion criteria: * age 40-80 * indicated for diagnostic ultrasound related to carotid artery stenosis exclusion criteria: * pregnant women * prior carotid intervention

Keywords: diagnosis carotid artery disease auscultation sound
adaptation and implementation of an asd executive functioning intervention in children's mental health services

Conditions: Autism Spectrum Disorder; Mental Health Disorder; Executive Dysfunction

Summary: the purpose of this project is to conduct a feasibility test of an asd executive functioning intervention adapted for mental health settings, including examining the effectiveness and process of implementing this adapted intervention in community mental health programs.

this project will examine the implementation and effectiveness of an asd executive functioning intervention, entitled unstuck and on target, adapted for use in community mental health clinics. minimizing the impact of executive functioning deficits in youth has broad public health implications, including improving the effectiveness of mental health services for youth such as those with autism spectrum disorders (asd) and attention-deficit/hyperactivity disorder (adhd). improved executive functioning also has the potential for improvement in real-world functioning, including daily living skills, mental health, and educational outcomes. although unstuck and on target is an established evidence-based intervention, the effectiveness of this intervention in mental health settings has not been established. therefore, the primary aim is to collect data on implementation outcomes of the adapted intervention, including feasibility, utility, and therapist fidelity, in mental health settings. the secondary aim is to collect data on the preliminary effectiveness of unstuck and on target adapted for mental health settings. this study has the potential to make a significant impact by building local capacity to serve school-age children with executive functioning deficits in routine service settings, and advancing the science on the effectiveness of an established evidence-based practice (unstuck and on target) for specific services settings. it will also produce generalizable knowledge about implementation that can be applied for this population/setting.

Eligibility criteria:
inclusion criteria for therapists: 1. employed as staff or a trainee at participating clinic (publicly-funded mental health program) 2. employed for at least the next 7 months (i.e., practicum or internship not ending in next 7 months). 3. has an eligible client on current caseload (see below). inclusion criteria for child participants 1. child age 5-13 years. 2. has a current asd diagnosis on record. 3. english or spanish speaking. exclusion criteria for child/ parent participants 1. child does not present with executive functioning deficits. 2. child does not meet criteria for asd via case record, on the autism diagnostic observation scale or exhibit other clinical indicators of asd
method of level (mol) therapy for psychosis

Conditions: Psychosis

Summary: the study is a systematic case replication series of a new psychological therapy method of levels (mol) for people who experience psychosis. between 6 and 8 people with psychosis who receive services from cmht will be recruited. participants will complete baseline questionnaires measuring their symptoms and distress and will be offered up to 12 sessions of mol. following the completion of therapy they will complete the questionnaires measuring symptoms and distress again.

psychosis is an enduring and distressing mental illness which can cause high levels of disability. recommended treatments include antipsychotic medication and cognitive behaviour therapy (cbt). antipsychotic drugs cause serious negative side effects which are intolerable for some patients. cbt can be difficult to conduct in the presence of comorbid problems and can be too demanding for some patients. both medication and cbt sometimes fail to sufficiently reduce the symptoms. method of levels (mol) is a flexible, short-term, cognitive therapy informed by a theory that explains the underpinnings of psychological distress and the mechanisms of action in effective therapy. the purpose of the current study is to evaluate the utility of mol for individuals with non-affective psychosis who are under the care of secondary mental health services. a case series will explore the efficacy of mol for the levels of symptoms, distress and general functioning. mol will be offered to 6-8 individuals with psychosis within a flexible appointment scheduling system. levels of symptoms, distress and general functioning will be measured before and after treatment. open feedback interviews following the completion of treatment will allow us to evaluate the patients' experience of mol. the project will provide preliminary data which will inform clinical practice and contribute to large scale research of mol.

Eligibility criteria:
inclusion criteria: * participants have to be registered with a community mental health services * participants need to either meet icd-10 criteria for schizophrenia, schizoaffective disorder and delusional disorder or meet entry criteria for an early intervention for psychosis service. exclusion criteria: * known moderate to severe learning disability * known organic basis of symptoms * known lack of capacity to consent to participating in research * lack of fluency in english (since mol therapy will be conducted in english and due to use of standardised assessment tools). this will be determined by the researcher. * acute inpatient status * a primary diagnosis of a drug or alcohol dependency * concurrent psychological therapy.
very low frequency magnetic fields versus the supplement "xinepa" in the treatment of the carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the purpose of the study is to determine the effectiveness of the treatment with very low frequency magnetic fields (elf) on the reduction of pain and the relief of the associated signs such as sensitivity disorders that affect the first three fingers and half of the fourth finger of the hand in patients with carpal tunnel syndrome versus the supplement (= xinepa).


Eligibility criteria:
inclusion criteria: * diagnosis of carpal tunnel syndrome exclusion criteria: * pregnancy; * pacemaker or other metallic implants; * systemic infectious disorders; * neoplastic disorders; * epilepsy; * severe heart disease. * known hypersensitivity to the components of xinepa

Keywords: magnetic fields pain paresthesia visual analogue scale
liposomal bupivacaine vs ropivacaine for tapbs

Conditions: Abdominal Tumor; Postoperative Analgesia; Liposomal Bupivacaine; Ropivacaine

Summary: few studies have compared the efficacy of ultrasound (us)-guided tap blocks with liposomal bupivacaine(lb) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor resection. therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of lb and ropivacaine for tap blocks among patients undergoing laparoscopic colorectal procedures.

this study aimed to investigate the impact of liposomal bupivacaine (lb) on postoperative opioid usage for ultrasound(us)-guided transversus abdominis plane (tap) blocks in laparoscopic colorectal resections. we divided 76 patients into two groups. an injection of bilateral tap blocks was administered to lb group using 133mg liposomal bupivacaine in each block (266mg total), and to r group using 20 ml 0.25% ropivacaine in each block (40 ml total). opioid consumption and pain scores at 6h, 24h, 48h and 72h were recorded postoperatively, as well as the total intraoperative remifentanil dose, the hospital stay lengths after surgery, and adverse events including dizziness, nausea, and vomiting.

Eligibility criteria:
inclusion criteria: 1. patients undergoing laparoscopic resection of lower abdominal tumors 2. asa grade ii-iii 3. age: 18-70 years. exclusion criteria: 1. (1) the patient does not agree to participate in the clinical study 2. (2) the patient has a clear history of opioid tolerance or allergy 3. (3) the patient has a history of local anesthetic allergy 4. (4) previous history of dementia, mental illness or other central nervous system diseases 5. (5) have a history of chronic pain or are taking opioids and other analgesics 6. (6) patients are generally in poor condition with a history of serious diseases of cardiovascular system, respiratory system, digestive system, urinary system or central nervous system, and may not survive for more than 3 months 7. (7) the patient had any of the following conditions in the 12 months before surgery: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism 8. (8) pregnant women 9. (9) unable to cooperate with follow-up or poor compliance 10. (10) patients with acute myocardial infarction, cardiac arrest or shock during surgery or hospitalization 11. (11) asa score above grade iii.

Keywords: liposomal bupivacaine ropivacaine transversus abdominis plane block laparoscopic lower abdominal tumor resection opioid consumption